Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02566252 · ClinicalTrials.gov registry record · Phase 1
Effect of Pre-Treatment With Cromolyn or Albuterol on Response to PUL-042 Inhalation Solution (PUL-042)
A Phase 1 study, sponsored by Pulmotect.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02566252 is a Phase 1 study that has completed, run by Pulmotect. The registered enrollment target is 16 participants.
The verdict
NCT02566252, a Phase 1 study, has completed, sponsored by Pulmotect.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study evaluates the effect of pre-treatment with either cromolyn sodium or albuterol sulfate on the safety and tolerability or PUL-042 Inhalation Solution in healthy subjects.
Interventions
- DRUG Albuterol sulfate
- DRUG PUL-042 Inhalation Solution
- DRUG Cromolyn Sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02566252
The ClinicalTrials.gov registry entry for NCT02566252 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pulmotect, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Albuterol sulfate is the first listed.
NCT02566252 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02566252 about?
NCT02566252 is a clinical study titled "Effect of Pre-Treatment With Cromolyn or Albuterol on Response to PUL-042 Inhalation Solution (PUL-042)". This study evaluates the effect of pre-treatment with either cromolyn sodium or albuterol sulfate on the safety and tolerability or PUL-042 Inhalation Solution in healthy subjects.
What is the current status of trial NCT02566252?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2015-07. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02566252?
The interventions under investigation include: Albuterol sulfate (DRUG), PUL-042 Inhalation Solution (DRUG), Cromolyn Sodium (DRUG).
Who is sponsoring clinical trial NCT02566252?
This trial is sponsored by Pulmotect, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.